| Name | Title | Contact Details |
|---|---|---|
Claire Freitag |
Vice President of Quality | Profile |
Jason Johnson |
CIO and Director of IT | Profile |
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
Chi Scientific is a Maynard, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ibidi is a Verona, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.